Harbor Capital Advisors Inc. Has $4.20 Million Position in Boston Scientific Co. (NYSE:BSX)

Harbor Capital Advisors Inc. lifted its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 2.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,023 shares of the medical equipment provider’s stock after buying an additional 1,153 shares during the period. Harbor Capital Advisors Inc.’s holdings in Boston Scientific were worth $4,200,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of BSX. Wealth Enhancement Advisory Services LLC grew its stake in Boston Scientific by 0.7% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 159,714 shares of the medical equipment provider’s stock valued at $13,384,000 after purchasing an additional 1,176 shares in the last quarter. Fortitude Family Office LLC grew its stake in shares of Boston Scientific by 62.0% in the fourth quarter. Fortitude Family Office LLC now owns 481 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 184 shares in the last quarter. Collective Family Office LLC acquired a new position in Boston Scientific during the fourth quarter worth $209,000. Bank of New Hampshire raised its position in Boston Scientific by 14.8% during the fourth quarter. Bank of New Hampshire now owns 2,565 shares of the medical equipment provider’s stock worth $229,000 after acquiring an additional 330 shares in the last quarter. Finally, CWA Asset Management Group LLC lifted its stake in Boston Scientific by 4.2% in the fourth quarter. CWA Asset Management Group LLC now owns 8,281 shares of the medical equipment provider’s stock valued at $740,000 after acquiring an additional 336 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent analyst reports. TD Cowen boosted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Thursday, December 12th. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Royal Bank of Canada raised their price objective on Boston Scientific from $95.00 to $98.00 and gave the company an “outperform” rating in a research report on Thursday, October 24th. Citigroup boosted their target price on Boston Scientific from $98.00 to $107.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, StockNews.com downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Monday, November 4th. Three research analysts have rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $97.26.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig sold 4,877 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the transaction, the director now directly owns 39,398 shares in the company, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the transaction, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 29,989 shares of company stock worth $2,702,261 in the last ninety days. 0.50% of the stock is owned by insiders.

Boston Scientific Trading Down 0.8 %

Shares of Boston Scientific stock opened at $95.14 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 12-month low of $59.39 and a 12-month high of $97.13. The company has a market capitalization of $140.22 billion, a price-to-earnings ratio of 78.63, a PEG ratio of 2.67 and a beta of 0.80. The firm’s 50-day moving average price is $89.96 and its two-hundred day moving average price is $83.80.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The business had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.04 billion. During the same quarter last year, the business posted $0.50 EPS. The firm’s revenue for the quarter was up 19.3% on a year-over-year basis. On average, analysts forecast that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.